Zota Health Care Acquires 20.2 Lakh Shares in Wholly Owned Subsidiary Curexis Ventures
Zota Health Care Limited acquired 20,20,000 equity shares in its wholly-owned subsidiary, Curexis Ventures Private Limited, via a rights issue for ₹4.04 crore. The subsidiary reported FY26 turnover of ₹1.18 lakhs and has a paid-up share capital of ₹1.01 lakhs. This investment aims to reduce group debt and improve net worth.
The acquisition of shares in a wholly-owned subsidiary, while strategically sound for debt reduction and net worth improvement, involves a relatively small financial amount compared to the overall company size, hence a medium impact.
The acquisition is positive as it strengthens the company's control over its subsidiary and is expected to reduce consolidated debt and improve net worth.
Zota Health Care Limited has announced the acquisition of 20,20,000 equity shares in its wholly-owned subsidiary, Curexis Ventures Private Limited. This acquisition was made through a subscription to a rights issue. Curexis Ventures Private Limited is involved in drug manufacturing, development, and marketing, and operates retail pharmacy stores under the brand name “SKIA”.
For the Financial Year 2025-26, Curexis Ventures Private Limited reported a turnover of ₹1.18 lakhs and its total paid-up share capital stands at ₹1.01 lakhs. The company is subscribing to equity shares on a rights basis, which the subsidiary will utilize for the repayment of outstanding unsecured loans availed from Zota Health Care Limited. This investment is expected to reduce the Group’s consolidated outstanding debt and improve its net worth. The transaction does not fall within related party transactions, and promoters or group companies have no interest in Curexis Ventures Private Limited, with the transaction being conducted on an arm's length basis.
The cost of acquisition for the 20,20,000 equity shares, offered at ₹20.00 per share (including a premium of ₹10.00), amounts to ₹4,04,00,000.00. The acquisition was completed on October 01, 2026, and Curexis Ventures Private Limited continues to remain a wholly-owned subsidiary of Zota Health Care Limited post-acquisition.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.